Page 264 - Read Online

Page 16 of 19 Mondal et al. Neuroimmunol Neuroinflammation 2018;5:34 I http://dx.doi.org/10.20517/2347-8659.2018.13

DECLARATIONS
Acknowledgements
The authors are grateful to Prof. Samaresh Chaudhuri for his inspiration and overall guidance to take up
this study and to Prof. Nandita Basu, Director, Calcutta School of Tropical Medicine, for providing all the
facilities required for the study. The authors are also thankful to West Bengal University of Health Sciences
for their kind approval to pursue this study.

Authors’ contributions
Conducted experiments and provided results: Mondal S, Datta A, Hazra I, Omar Faruk SM, Moitra S,
Chaudhuri S, Nath L, Das PK, Basu AK
Co-wrote the first draft: Mondal S
Edited the manuscript: Chaudhuri S
Co-supervised aspects of the project: Tripathi SK
Provided overall supervision of the project, edited and finalized the manuscript: Chaudhuri S

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work has been supported by a research grant (Sanction Order for Grant-in-Aid No 563-BT (Estt.)/RD-
3/13 dated 23.08.2013) from the West Bengal Department of Biotechnology, Government of West Bengal.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
All studies involving animals were reviewed and approved by Institutional Ethical Committee at Calcutta
School of Tropical Medicine, Kolkata, West Bengal, India, monitored by Committee for the Purpose of
Control and Supervision of Experiments on Animals, Govt. of India (CPCSEA) regulations.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCE
1. Waziri A. Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am 2010;21:31-42.
2. Taniguchi Y, Ono K, Yoshida S, Tanaka R. Antigen-presenting capability of glial cells under glioma-harboring conditions and the effect
of glioma-derived factors on antigen presentation. J Neuroimmunol 2000;111:177-85.
3. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1
expression in tumor-associated macrophages. Clin Cancer Res 2013;19:3165-75.
4. Castro MG, Baker GJ, Lowenstein PR. Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier! Clin
Cancer Res 2014;20:5147-9.
5. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic
CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.
Clin Cancer Res 2007;13:2158-67.
6. Zhang Y, Wang C, Zhang Y, Sun M. C6 glioma cells retrovirally engineered to express IL-18 and Fas exert FasL-dependent cytotoxicity
against glioma formation. Biochem Biophys Res Commun 2004;325:1240-5.
7. Crane CA, Ahn BJ, Han SJ, Parsa AT. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion
of regulatory T cells: implications for immunotherapy. Neuro Oncol 2012;14:584-95.